News & Events
< Back to News Overview
Xenome - Addition to US patent portfolio for Xen2174
23 / 03 / 2009
Xenome Limited ("Xenome") today announced the issuance of US patent 7,507,717 entitled "Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)".
This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, the Company's lead molecule. Xen2174 has shown promise as a bestin-class pain therapeutic and is currently in clinical development for the treatment of moderate to severe pain in various acute and chronic pain indications.
The newly issued patent provides Xenome with a proprietary position on multiple families of analogues of the chi-conotoxin, Mr1A, through to the end of 2025. These peptides have the
ability to inhibit the noradrenaline transporter, also known as the norepinephrine transporter (NET).
"This patent strengthens our web of intellectual property surrounding Xen2174", stated Xenome's Chief Executive Officer, Dr Ian Nisbet. "The fact that we have multiple issued US
patents, as well as patents in other territories, will be highly valued by potential partners."
This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, the Company's lead molecule. Xen2174 has shown promise as a bestin-class pain therapeutic and is currently in clinical development for the treatment of moderate to severe pain in various acute and chronic pain indications.
The newly issued patent provides Xenome with a proprietary position on multiple families of analogues of the chi-conotoxin, Mr1A, through to the end of 2025. These peptides have the
ability to inhibit the noradrenaline transporter, also known as the norepinephrine transporter (NET).
"This patent strengthens our web of intellectual property surrounding Xen2174", stated Xenome's Chief Executive Officer, Dr Ian Nisbet. "The fact that we have multiple issued US
patents, as well as patents in other territories, will be highly valued by potential partners."